Global Patent Index - EP 4275749 A2

EP 4275749 A2 20231115 - TREATING NEUROPATHIC PAIN ASSOCIATED WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY

Title (en)

TREATING NEUROPATHIC PAIN ASSOCIATED WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY

Title (de)

BEHANDLUNG VON NEUROPATHISCHEN SCHMERZEN IM ZUSAMMENHANG MIT CHEMOTHERAPIE-INDUZIERTER PERIPHERER NEUROPATHIE

Title (fr)

TRAITEMENT DE LA DOULEUR NEUROPATHIQUE ASSOCIÉE À LA NEUROPATHIE PÉRIPHÉRIQUE INDUITE PAR LA CHIMIOTHÉRAPIE

Publication

EP 4275749 A2 20231115 (EN)

Application

EP 23177475 A 20220523

Priority

  • US 202163192246 P 20210524
  • EP 22730040 A 20220523
  • US 2022072496 W 20220523

Abstract (en)

The invention features methods of preventing and/or treating neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN).

IPC 8 full level

A61P 25/02 (2006.01)

CPC (source: EP US)

A61K 31/661 (2013.01 - EP); A61K 31/683 (2013.01 - US); A61P 25/02 (2018.01 - EP US)

Citation (applicant)

  • US 194662631922 P
  • WO 2019067919 A1 20190404 - MEDICON PHARMACEUTICALS INC [US]
  • US 8236820 B2 20120807 - RIGAS BASIL [US]
  • MOORE ET AL., COCHRANE DATABASE OF SYSTEMATIC REVIEWS, vol. 10, 2015, pages 1 - 25
  • MACKENZIE ET AL., GASTROENTEROLOGY, vol. 139, no. 4, 2010, pages 1320 - 32
  • MATTHEOLABAKIS ET AL., PHARM RES, vol. 30, no. 6, 2013, pages 1471 - 82
  • HIDAKA ET AL., EUROPEAN JOURNAL OF PAIN, vol. 13, no. 1, 2012, pages 22 - 27
  • BONIN ET AL., MOLECULAR PAIN, vol. 10, no. 26, 2014, pages 1 - 10
  • HIDAKA ET AL., EUROPEAN JOURNAL OF PAIN, vol. 13, 2009, pages 22 - 27
  • CAROZZI ET AL., EXP NEUROL, vol. 226, 2010, pages 301 - 309
  • CURRIE ET AL., PLOS BIOL, vol. 17, 2019, pages e3000243
  • ELDRIDGE ET AL., TOXICOL PATHOL, vol. 48, 2020, pages 190 - 201
  • CHAPLAN ET AL., J NEUROSCI METHODS, vol. 53, 1994, pages 55 - 63
  • BAGDAS ET AL., BIOCHEM PHARMACO, vol. 97, 2015, pages 590 - 600
  • WEN ET AL., INT J PHARM, vol. 557, 2019, pages 273 - 279
  • XIE ET AL., BR J PHARMACOL, vol. 165, 2012, pages 2152 - 2166
  • TOMA W ET AL., NEUROPHARMACOLOGY, vol. 117, 2017, pages 305 - 15

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

WO 2022251805 A1 20221201; AU 2022283458 A1 20240118; BR 112023024422 A2 20240220; CA 3220195 A1 20221201; CN 117377476 A 20240109; DK 4114403 T3 20230724; EP 4114403 A1 20230111; EP 4114403 B1 20230607; EP 4275749 A2 20231115; EP 4275749 A3 20240103; ES 2952672 T3 20231103; FI 4114403 T3 20230727; HR P20230541 T1 20230929; HU E062891 T2 20231228; JP 2024520463 A 20240524; KR 20240013092 A 20240130; LT 4114403 T 20230925; MA 58889 B1 20230628; MD 4114403 T2 20240831; MX 2023013855 A 20231208; PL 4114403 T3 20231009; PT 4114403 T 20230817; RS 64471 B1 20230929; SI 4114403 T1 20231030; US 2024180936 A1 20240606

DOCDB simple family (application)

US 2022072496 W 20220523; AU 2022283458 A 20220523; BR 112023024422 A 20220523; CA 3220195 A 20220523; CN 202280037433 A 20220523; DK 22730040 T 20220523; EP 22730040 A 20220523; EP 23177475 A 20220523; ES 22730040 T 20220523; FI 22730040 T 20220523; HR P20230541 T 20220523; HU E22730040 A 20220523; JP 2023572970 A 20220523; KR 20237034666 A 20220523; LT US2022072496 T 20220523; MA 58889 A 20220523; MD E20230064 T 20220523; MX 2023013855 A 20220523; PL 22730040 T 20220523; PT 22730040 T 20220523; RS P20230459 A 20220523; SI 202230002 T 20220523; US 202318515734 A 20231121